PMID: 38412860 GPR133 is hypomethylated and upregulated in decidual macrophages in recurrent spontaneous

technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents

(PLC) is thought to have a key role in the cardiomyocyte response to several different hypertrophic agents

We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related

"Modulators of the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents

Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated

In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.

These insights will facilitate further development of therapeutic agents targeting the DOR.Communicated

pathogenic fungi, including Hc, the ubiquitous fungal pathogen Candida albicans, and the causative agent

As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently

Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has

characterization of neuropeptides and their GPCRs in G. molesta; and to develop specific neuropeptide-based agents

presents a barrier that restricts the passage of large molecules, making it challenging to deliver tagging agents as nanoparticles or liposomes, capable of penetrating cellular membranes and delivering the tagging agents

enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic agents

epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic agents

GPCR Binders, Drugs, and more A snake toxin as a theranostic agent for the type 2 vasopressin receptor

theoretically offer several advantages compared to orthosteric ligands when considered as potential therapeutic agents

Russell to Board of Directors Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral Agent

Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency GLOBE NEWSWIRE) -- ChemoCentryx , Inc. , (Nasdaq: CCXI), today announced that the European Medicines Agency

spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency